HOME >> MEDICINE >> NEWS
Mayo Clinic researchers report on effectiveness of treatments for hot flashes

; Sunday, May 15, 2005, 8 a.m. EDT

NCCTG Study Compares Venlafaxine and Progestational Agents in Reducing Hot Flashes

Mayo Clinic researchers will outline current data comparing the effectiveness of two medicines -- venlafaxine and a progestational agent -- in combating hot flashes.

Previous studies have shown that both venlafaxine and progestational agents substantially decrease hot flashes. This NCCTG trial demonstrated that a single dose of the progestational agent, medroxyprogesterone acetate (MPA), alleviated hot flashes more than did the daily use of the oral antidepressant venlafaxine (Effexor). Three to four weeks after treatment began, researchers observed that MPA was more effective than venlafaxine. This difference became even more striking after six weeks of treatment, says Mayo medical oncologist Charles Loprinzi, M.D., the NCCTG study's lead investigator.

"This improved hot flash benefit appeared to last for at least six months following a single MPA dose, with almost three times as many patients still reporting a 90 percent hot flash reduction following MPA versus patients receiving daily oral venlafaxine," says Dr. Loprinzi.

The findings reviewed in this presentation include data from 185 patients. Six weeks after treatment was started (compared to the baseline week), patients who received the single shot of MPA, versus those on venlafaxine, had greater reductions in median hot flash frequencies (85 percent vs. 52 percent reduction) and reductions in median hot flash scores (88 percent vs. 57 percent reduction).

Mayo researchers also noted that 24 percent of patients who received MPA reported no hot flashes after six weeks compared to 1 percent of venlafaxine patients. Patients on MPA also reported less trouble sleeping, less sleepiness, less constipation, less abnormal sweating and less hot flash distress than patients on venlafaxine.

The patients on venlafaxine had trends for less trou
'"/>


15-May-2005


Page: 1 2 3 4

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. New Mayo Clinic MRI technology enables noninvasive liver diagnoses
6. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
7. Elsevier launches the Clinics on ScienceDirect
8. Clinical guidelines for blood conservation during cardiac procedures developed
9. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
10. Mayo Clinic research in cardiovascular disease presented at Experimental Biology 2007
11. Mayo Clinic study finds heart transplant patients benefit from new approach to immunosuppression

Post Your Comments:
(Date:7/2/2015)... ... July 02, 2015 , ... “ LIFX ” was featured on NewsWatch ... products available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, ... versatile smart light bulbs on the market. , According to the U.S. Department of ...
(Date:7/2/2015)... PEACHTREE CITY, GA (PRWEB) , ... July 02, ... ... or field sporting the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the ... physicians, fitness experts and athletic trainers. Their significant popularity has inspired four new, ...
(Date:7/2/2015)... ... , ... Six months ahead of his 80th birthday, Don Stevenson has reached ... for the Pulmonary Hypertension Association (PHA). Stevenson began the walk in Washington State ... mid-September. He left Glasgow, Mont. yesterday morning and is making his way to Wolf ...
(Date:7/2/2015)... Diego, CA (PRWEB) , ... July 02, 2015 , ... ... and a passion for social fitness. Built to function as a lifestyle community, Active ... giving them the opportunity to network, meet, and participate in discussions or group events. ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... - pipeline review 2015” provides comprehensive information on the pipeline products with ... on negative pressure wound therapy (NPWT) with 22 market data tables and ...
Breaking Medicine News(10 mins):Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4
(Date:7/2/2015)...   , July 2, 2015 BGI ... Hong Kong has been accredited ... Kong facility is the first clinical next-generation-sequencing laboratory to ... , meeting the highest standard in clinical laboratory practices. Complementary ... 11 compliant laboratory process, and multiple ISO certifications, the ...
(Date:7/2/2015)...   Wilson Therapeutics AB , a privately-held biopharmaceutical ... its board of directors. The appointment was approved by ... 30. "We are delighted to welcome Hans ... , CEO of Wilson Therapeutics. "Hans brings significant global ... to his contributions to the Company." Hans ...
(Date:7/1/2015)... 1, 2015 The Coalition of State ... and regional professional rheumatology societies, today released the ... explored perceptions of biosimilars and the potential impact ... Biosimilars are medicines that are highly similar, ... notably different from generic medications in that it ...
Breaking Medicine Technology:BGI Receives Accreditation from the College of American Pathologists (CAP) 2Wilson Therapeutics Appoints Hans Schikan to its Board of Directors 2Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2
Cached News: